Загрузка...
Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase
Despite the success of imatinib at inhibiting Bcr-Abl and treating chronic myelogenous leukemia (CML), resistance to the therapy occurs over time in patients. In particular, the resistance to imatinib caused by the gatekeeper mutation T315I in Bcr-Abl remains a challenge in the clinic. Inspired by t...
Сохранить в:
| Опубликовано в: : | J Med Chem |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7475166/ https://ncbi.nlm.nih.gov/pubmed/26562217 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.5b01125 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|